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Background: The effect of sublingual Timothy grass immunotherapy tablet 2800 BAU (grass SLIT-T) has been
evaluated in three North American trials in adults and children who have allergic rhinitis with or without
conjunctivitis (AR/C). This paper examines the effects of grass SLIT-T in Canadians.
Methods: Data for grass-allergic Canadians in three randomized, placebo-controlled, double-blind trials were
analyzed post hoc: 1) adults ≥18 y, grass-pollen season [GPS] 2009; 2) children 5– <18 y, 2009; and 3) adults 18–65
y and children 5– <18 y, GPS 2012. Data from the GPS 2009 trials were pooled to provide a more precise estimate
of treatment effects than the individual studies would provide. In every trial, participants received once-daily grass
SLIT-T or placebo approximately 12 weeks before and continuing throughout the GPS. Participants used daily
electronic diaries to record AR/C symptoms and medication use for treatment of symptoms. The therapeutic effect
of grass SLIT-T was measured as a total combined score (TCS = daily symptom score + daily medication score)
averaged over the entire GPS. Safety was assessed by monitoring adverse events (AEs).
Results: In the three trials, 386 Canadian participants were randomized; the overall population had 2284
participants. Canadian participants treated with grass SLIT-T in the pooled adult-pediatric 2009 trials showed a 38%
mean TCS reduction relative to placebo (−2.06 difference [95% CI: −3.72, −0.39]; 3.32 vs. 5.37). Participants treated
with grass SLIT-T in the adult-pediatric 2012 trial showed a 37% median TCS reduction relative to placebo (−1.53
difference [95% CI: −2.1, −0.3]; 2.58 vs. 4.11). Similar efficacy findings were observed over the peak GPS. Approximately
90% of treatment-related AEs were mild or moderate in severity. Two Canadian participants had moderate systemic
allergic reactions (skin, respiratory, abdominal symptoms) to grass SLIT-T; symptoms resolved within 1 hour without
medical intervention or treatment. No serious or life-threatening treatment-related AEs occurred.
Conclusion: The 2800 BAU Timothy grass SLIT-T significantly improved AR/C induced by Timothy grass pollen in adults
and children ≥5 y in Canadians, which was consistent with the robust efficacy observed in the overall trial population.
The treatment was generally well tolerated.
Trial registration: Clinicaltrials.gov identifiers NCT00562159, NCT00550550, NCT01385371.
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Upper respiratory allergies, including allergic rhinitis with
or without conjunctivitis (AR/C), are estimated to affect
20% to 25% of Canadians [1]. In the International Study of
Asthma and Allergies in Childhood, up to 24% of Canadian
children in two regions (Saskatoon, SK, and Vancouver,
BC) reported in 2003 that they “ever had hay fever” [2]. In
2013, however, the Public Health Agency of Canada re-
ported that nearly 50% of Canadian children have hay fever
[3]. AR/C is typically induced by inhalant allergens such as
dander, dust mites, and pollens. In North America, grass
pollen is one of the most common seasonal allergens that
cause allergic symptoms. Many patients with AR/C are
allergic to Timothy grass (Phleum pratense). Timothy
grass pollen is common in all Canadian provinces. In
Canada, the prevalence of sensitivity to grass pollen has
been found to vary between 14% and 30% in patients
with AR/C [4]. Timothy grass is highly cross-reactive
with other Northern pasture grasses, such as perennial
rye, meadow fescue, bluegrass/june, orchard/cocksfoot,
redtop/bent/velvet, and sweet vernal [5-7]; studies of
single-grass (ie, Timothy) immunotherapy have demon-
strated efficacy against these temperate grasses.
The most common treatment for allergic rhinitis con-
sists of pharmacotherapy. However, as reported in the
2006 Allergies in Canada survey on use of nasal allergy
medications, at least two-thirds of participants reported
that, even with proper pharmacotherapy, nasal allergic
symptoms are associated with lifestyle limitations [8].
Unlike pharmacotherapy, allergen immunotherapy modu-
lates the basic immunologic mechanisms of the allergic
disease. Therefore, grass allergen immunotherapy is an
important alternative or complementary treatment to
pharmacotherapy, with a distinct mechanism of action
that induces a sustained long-term effect even after
treatment. It is the only treatment known to provide
long-term benefit and alter the course of respiratory
allergic disease when used in a sustained fashion that is
different from what is being presented here [9-12].
One purported advantage of sublingual administra-
tion versus subcutaneous immunotherapy administra-
tion is improved safety, allowing for self-administration
at home after treatment is initiated under physician
supervision [12]. Although sublingual immunotherapy
tablets (SLIT-T) have been in use in Europe for several
years, the experience with Timothy grass immunother-
apy tablet in Canadian and US subjects is limited. Given
the prevalence of AR in Canada [2] and the relatively
small number of AR clinical trials conducted in Canada
from 2001 to 2011 [13], it was of interest to determine
if SLIT-T would reduce AR symptoms and medication
use in Canadian participants. The efficacy and safety of
the Timothy grass 2800 BAU SLIT-T, which dissolves
within seconds [14], has been investigated in 3 NorthAmerican trials in which it was found to be effective and
well tolerated for participants with grass-pollen–induced
AR/C [14-16]. This paper presents results of a post hoc
analysis to assess the efficacy of grass SLIT-T for the treat-
ment of grass-pollen–induced AR/C for Canadian partici-
pants enrolled in these 3 randomized, placebo-controlled,
double-blind trials. The results are from 2 trials conducted
during the 2009 grass pollen season (GPS) and 1 trial con-
ducted during the 2012 GPS, which is the largest SLIT-T
trial ever conducted [14].
Methods
Post hoc analysis design
A post hoc analysis of key efficacy endpoints for the
subgroup of Canadian participants was performed for 3
studies of similar design conducted in 2009 or 2012.
One 2009 study (P05238; clinicaltrials.gov registration
NCT00562159) involved adults (aged 18–65 y) from 9
centers in Canada, and the other 2009 study (P05239;
clinicaltrials.gov registration NCT00550550) involved chil-
dren and adolescents (aged 5–17 years) from 10 centers in
Canada. The 2012 study (P08067; clinicaltrials.gov regis-
tration NCT01385371) had a population which involved
participants of all age groups (aged 5–65 years) from 25
centers in Canada. All participants had symptoms of grass-
pollen–induced AR/C with or without asthma. Sensitivity
to grass was confirmed by IgE reactivity to Timothy grass
extract (average skin prick test wheal diameter ≥5 mm lar-
ger than saline control after 15–20 min and serum-specific
IgE to Phleum pretense ≥0.7 kU/L). A washout period (≥30
days) for inhaled corticosteroids was required before the
preseasonal visit (approximately 2 weeks before the start of
the GPS) [14]. Study methods have been published/pre-
sented for each study and are described elsewhere [14-16].
Data for Canadian participants in the 2 trials conducted
in the 2009 GPS were pooled for the present analysis.
Pooling of these 2 trials from the same season delivers a
more precise estimate of treatment effects than could be
provided by the individual 2009 trials, which had small
Canadian subpopulations. In addition, pooling of results
from the adult and pediatric 2009 trials permits side-by-
side examination of these results with those from the
adult-pediatric 2012 trial in a uniform population of Can-
adian children/adolescents and adults (aged 5–65 y) across
different pollen seasons, as it is known that grass pollen
levels may influence study outcomes [17].
Design of trials included in the post hoc analysis
The primary hypothesis tested for each of the 3 trials was
that administration of Timothy grass 2800 BAU SLIT-T
compared with placebo would result in superior improve-
ment in total combined score (TCS; rhinoconjunctivitis
daily symptom score [DSS] plus daily medication score
[DMS]) averaged over the entire GPS. The studies were
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and in compliance with Good Clinical Practice guidelines.
The protocol was approved by institutional review boards
for each center. Randomized subjects were treated once
daily with either grass SLIT-T or placebo for approxi-
mately 12 or 16 weeks before the GPS and through the
entire GPS, for a total of ≥23 weeks post-randomization.
Grass SLIT-T does not require up-titration, as the first
dose is considered the maintenance dose and if tolerated
will not require participant dose adjustments subsequently
(eg, during season). The first 3 consecutive daily doses of
grass SLIT-T were administered at the physician’s office in
the pooled adult-pediatric 2009 trials, while only the first
dose was administered in the physician’s office in the adult-
pediatric 2012 trial due to the overall favorable safety profile
shown in previous studies [15,16]. Following initial super-
vised tablet administration in the three trials, all subsequent
doses were self-administered by participants or their guard-
ians (in the case of children) at home. As an added safety
precaution, participants were supplied with self-injectable
epinephrine and instructed to have it available for up to 30
minutes after daily dosing; they were also given instructions
on how and when to use it. In addition, open-label rescue
medications for AR/C and asthma symptoms were pro-
vided and allowed to be used during the GPS.
Grass-pollen season
The GPS was defined as beginning on the first of 3 con-
secutive days with a grass-pollen count ≥10 grains/m3
and ending on the last day of the last occurrence of 3 con-
secutive days with a grass-pollen count ≥10 grains/m3.
Peak season was defined as the 15 consecutive days within
GPS with the highest 15-day moving average pollen count
for each site.
Clinical efficacy assessments
The primary efficacy endpoint in all 3 trials was the
TCS averaged over the entire GPS. Key secondary effi-
cacy endpoints in all 3 trials, which were analyzed only
if the primary efficacy analysis was significant, were the
entire-season DSS, the entire-season DMS, and the
peak-season Rhinoconjunctivitis Quality of Life Question-
naire score (not reported here). The peak-season TCS was
a key secondary endpoint in the adult-pediatric 2012 trial
and a secondary endpoint in the pooled adult-pediatric
2009 trials. Peak-season DSS and DMS were secondary
endpoints in all 3 trials [14-16].
Symptoms and medication use were recorded once
daily in the evening before bed in an electronic diary.
Safety endpoints included adverse events (AEs) [14-16].
Statistical analysis
For the 2 pooled adult-pediatric 2009 trials, the primary
and secondary efficacy endpoints were evaluated using alinear model with asthma status, study site, and treat-
ment group as fixed effects. The efficacy analysis for all
trials was in the full-analysis set population (≥1 dose of
study medication and ≥1 efficacy measure during GPS),
based on the intent-to-treat principle. Subjects were ana-
lyzed according to the treatment arm to which they were
randomized. Subjects were included in the entire-season
or peak-season analysis if they had at least one post-
baseline diary record within the defined pollen season. A
two-sided 95% CI of the difference in adjusted means
between the two treatment groups was presented. For
the 2012 between-treatment comparison, the point esti-
mate of the treatment difference was based on the median
and the 95% CI for the median difference was based on
the Hodges-Lehmann estimator. Median scores within
each group were reported to represent the treatment effect
for TCS and DSS; the average DMS over the entire GPS
was analyzed using a zero-inflated log-normal model due
to excessive 0 values in the data; the model adjusted for
treatment, baseline asthma status, age category (<18
years or ≥18 years), and pollen region as covariates.
Nominal P values are reported for the between-treatment
differences. No adjustment in multiplicity is made due to
post hoc nature of these analyses.
Results
Baseline demographics
The Canadian subpopulation randomized to grass SLIT-
T or placebo included 386 participants across three tri-
als. The pooled adult-pediatric 2009 trials had 57 adults
and 46 children, and the adult-pediatric 2012 trial had
262 adults and 21 children (Table 1). Participants were
randomized in the provinces of Ontario and Quebec in
the 2009 trials and the provinces of Ontario, Quebec,
and British Columbia in the 2012 trial.
Grass-pollen season
The 2009 GPS in Canada had low mean pollen counts of
19 to 21 grains/m3 over the entire season, which lasted a
median of 52 to 57 days in North America overall. The
2012 GPS in Canada had mean pollen counts of approxi-
mately 23 grains/m3 over the entire season which lasted a
median of 55 days in North America overall. Both of these
grass pollen seasons in North America were characterized
by few pollen peaks, with average peak season counts of
40 and 53 grains/m3, respectively, in 2009 and 2012.
Primary efficacy results
Canadian participants taking grass SLIT-T (n =42) in
the pooled adult-pediatric 2009 trials showed a 38%
mean TCS reduction relative to placebo (n =54), with
a −2.06 difference (95% CI: −3.72, −0.39) between grass
SLIT-T (3.32) and placebo (5.37; Figure 1). Canadian
participants taking grass SLIT-T (n =122) in the adult-
Table 1 Demographics and baseline characteristics of the Canadian subgroup in all three trials
2009 studies 2012 study
Adults Children Adults + children*
Characteristic Placebo (n =33) Grass SLIT-T (n =24) Placebo (n =23) Grass SLIT-T (n =23) Placebo (n =141) Grass SLIT-T (n =142)
Male, % 45 46 57 61 59 49
Age, mean y 35.6 32.8 12.4 11.0 35.7 33.6
White, % 82 92 91 87 81 85
Asthma, % 36 25 17 17 21 25
Polysensitized, % 88 96 91 74 89 89
*The 2012 study involved 262 adults and 21 children.
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tion relative to placebo (n =122), with a −1.53 difference
(95% CI: −2.1, −0.3) between grass SLIT-T (2.58) and
placebo (4.11; Figure 1).
Secondary efficacy results
In addition to the greater reduction of TCS for grass SLIT-
T versus placebo in all 3 trials, the pooled adult-pediatric
2009 trials found that grass SLIT-T reduced the DSS
(−38%; p = .013) and DMS (−39%; p = .238) compared with
placebo over the entire season in the Canadian subgroup
(Figure 2A). Moreover, in the Canadian subgroup of the
adult-pediatric 2012 trial, grass SLIT-T reduced the entire-
season DSS (−32%; p = .027) and DMS (−52%; p = .011)
compared with placebo (Figure 2B).
These patterns of improvement were also seen in the effi-
cacy results over the peak GPS. In the pooled adult-
pediatric 2009 trials, peak-season reductions for grass
SLIT-T versus placebo in TCS, DSS, and DMS ranged from
40% to 60% in the Canadian subgroup (Table 2). In the








































Figure 1 TCS in Canadian participants over the entire grass pollen seas
2012 trial.season reductions for MK-7243 versus placebo ranged from
17% to 54% in the Canadian subgroup (Table 2). These
results for the peak GPS indicate that grass SLIT-T is also
effective at reducing AR/C symptoms and the need for res-
cue medications when allergen exposure is at its highest.
Safety results
Grass SLIT-T was well tolerated in the Canadian sub-
population, with treatment-related AEs (TRAEs) that
were generally mild to moderate in severity. No Canad-
ian participant in the pooled adult-pediatric 2009 trials
reported a severe AE, and only 3 grass SLIT-T partici-
pants and 2 placebo participants in the adult-pediatric
2012 trial reported a severe AE, none of which were
treatment-related. Treatment-emergent AEs (TEAEs)
were mainly transient local reactions in the mouth,
throat, and ear. For Canadians in the pooled 2009 trials,
66% and 45%, respectively, of the grass SLIT-T and
placebo groups had any TEAE, whereas 45% and 14%,
respectively, of the grass SLIT-T and placebo groups
had a TRAE. In the adult-pediatric 2012 trial, 66% of4.11
2.58






















































































































Figure 2 Symptom and medication scores in Canadian participants over the entire grass pollen season in the pooled adult-pediatric
2009 trials (A) and the adult-pediatric 2012 trial (B).
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had any TEAE, whereas 49% of the grass SLIT-T group
and 23% of the placebo group had a TRAE (Table 3).
In the Canadian subpopulation across the 3 trials, 9
(4.8%) participants taking grass SLIT-T and 6 (3.0%) par-
ticipants taking placebo discontinued treatment due to
AEs. In the pooled adult-pediatric 2009 trials, one 9-
year-old male receiving grass SLIT-T discontinued treat-
ment due to dysphagia, ear pruritus, and throat irritation
probably related to treatment, and one participant re-
ceiving placebo discontinued due to anxiety that was un-
likely related to treatment. In the adult-pediatric 2012
trial, 8 grass SLIT-T participants and 5 placebo partici-
pants discontinued due to AEs. In the grass SLIT-T group,
AEs leading to discontinuation primarily were localallergic reactions (eg, oral pruritus, ear pruritus, and throat
irritation). Two adult participants in the adult-pediatric 2012
trial discontinued treatment for events judged to be systemic
allergic reactions. One participant in the adult-pediatric
2012 trial discontinued treatment after experiencing mild
edema on the lower lips, redness on mouth corners and
chin, epigastric discomfort, and dizziness following the sec-
ond dose of grass SLIT-T. The second participant developed
chest tightness and shortness of breath after grass SLIT-T.
Both of these events self-resolved without treatment.
None of these AEs were life-threatening, and there were
no cases of anaphylactic shock. No participants in any of
the 3 studies had serious TRAEs. None of the Canadian
participants used epinephrine for AE relief in the 3 trials,
although one adult participant in the pooled adult-
Table 2 TCS, DSS, and DMS during the entire and peak grass pollen season in the Canadian subgroup in all three trials
Pooled adult-pediatric 2009 trials Adult-pediatric 2012 trial
Placebo Grass SLIT-T Placebo Grass SLIT-T
TCS – entire season
n 54 42 122 122
Mean (SE/SD)* 5.37 (0.68) 3.32 (0.65) 4.96 (4.22) 3.34 (2.93)
Median 3.88 1.46 4.11 2.58
Difference (95% CI)** −2.06 (−3.72, −0.39) −1.53 (−2.1, −0.3)
Relative difference* −38% −37%
p value .016 .005
DSS – entire season
n 54 42 122 122
Mean (SE/SD)* 4.31 (0.50) 2.69 (0.51) 3.48 (2.91) 2.59 (2.16)
Median 3.18 1.38 2.96 2.00
Difference (95% CI)** −1.63 (−2.89, −0.36) −0.95 (−1.3, −0.0)
Relative difference −38% −32%
p value .013 .027
DMS – entire season
n 54 42 122 122
Mean (SE/SD)* 1.09 (0.32) 0.67 (0.23) 1.30 (0.36) 0.62 (0.20)
Median 0.12 0.00 0.65 0.00
Difference (95% CI)** −0.42 (−1.12, 0.28) −0.68 (−1.20, −0.16)
Relative difference −39% −52%
p value .238 .011
TCS – Peak season
n 52 42 120 119
Mean (SE/SD)* 5.73 (0.78) 3.17 (0.62) 5.50 (4.93) 3.70 (3.40)
Median 3.93 1.47 4.48 3.13
Difference (95% CI)** −2.56 (−4.32, −0.81) −1.35 (−2.3, −0.2)
Relative difference −45% −30%
p value .005 .014
DSS – peak season
n 52 42 120 119
Mean (SE/SD)* 4.64 (0.59) 2.77 (0.51) 3.73 (3.29) 2.85 (2.37)
Median 3.33 1.21 2.93 2.43
Difference (95% CI)** −1.87 (−3.24, −0.50) −0.50 (−1.3, 0.1)
Relative difference −40% −17%
p value .008 .109
DMS – peak season
n 52 42 120 119
Mean (SE/SD)* 1.14 (0.35) 0.46 (0.21) 1.77 (2.61) 0.85 (1.87)
Median 0.00 0.00 0.55 0.00
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Table 2 TCS, DSS, and DMS during the entire and peak grass pollen season in the Canadian subgroup in all three trials
(Continued)
Difference (95% CI)** −0.68 (−1.42, 0.05) −1.13 (−1.94, −0.33)
Relative difference −60% −54%
p value .068 .006
*Adjusted means (SE) for the pooled adult-pediatric 2009 trials; raw means (SD) for the adult-pediatric 2012 trial.
**For the pooled adult-pediatric 2009 trials, analysis of variance model was used with asthma status, treatment group, and site as fixed effects and adjusting for
different error variation for each treatment group. For the adult-pediatric 2012 trial, the point estimate of the difference was based on the median; the 95% CI for
the median difference was based on the Hodges-Lehmann estimator for TCS and DSS. For DMS in this trial, a zero-inflated log-normal model was used with
asthma status, treatment group, age category and pollen region as fixed effects. Absolute and relative treatment differences are estimated based on this model,
and confidence intervals are estimated based on the model using the delta method.
DMS, daily medication score; DSS, daily symptom score; SD, standard deviation, SE, standard error; TCS, total combined score.
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anxiety attack, which is not an indicated or appropriate
use for this medication.
Discussion
In 3 trials, pooled results of treatment with Timothy
grass 2800 BAU SLIT-T, a new formulation and adminis-
tration of allergen immunotherapy, showed significant
improvement of symptoms and a reduction in the need
for pharmacotherapy caused by grass pollen in Canadian
adults and children aged 5 years and older. The symp-
tom improvement was in the context of participants
taking rescue medication for symptoms, and the change
with grass SLIT-T was seen on top of the effect obtained
with the rescue medication. The primary results in the
Canadian subgroup of the pooled adult-pediatric 2009
trials and the adult-pediatric 2012 trial confirm the
findings of North American and European trials. Reduc-
tions of entire-season TCS in the Canadian subgroup
ranged from 38% to 39% in the present post hoc ana-
lysis, and TCS reductions ranged from 20% to 26% in
the overall North American trials [14-16]. In European
trials, which had separate analyses of symptom andTable 3 Adverse events reported in the Canadian population
pediatric 2012 trial
Pooled adult-pediatric 2
Grass SLIT-T (n =47)
Any TEAE, n (%) 31 (66.0)
TRAE, n (%) 21 (44.7)
Discontinued due to TRAE, n (%) 1 (2.1)
Local application-site TRAE, n (%)
Oral pruritus 7 (14.9)
Ear pruritus 9 (19.1)
Edema mouth 0
Eye pruritus 0
Throat irritation 14 (29.8)
Nasal passage irritation 1 (2.1)
Skin pruritus 2 (4.3)
AE, adverse event; TEAE, treatment-emergent adverse event; TRAE, treatment-relatedmedication scores, reductions of DSS and DMS ranged
from 16% to 38% compared with placebo [18-21]. The
North American trials and Canadian subgroup analyses
are limited in that treatment effects over 1 season were
evaluated, although sustained efficacy has been demon-
strated over a 2-year follow up following 3 years of daily
treatment with Timothy grass SLIT-T [10]. Another
limitation is the nature of the post hoc analyses and the
fact that the sample size is relatively small in the Canadian
subgroup; therefore, results should be interpreted in terms
of overall trends in treatment effect.
The potential for disease modification with sublingual
immunotherapy should be considered when comparing
grass SLIT-T with medication to treat symptoms.
Immunotherapy has been shown to induce allergen-
specific IgG antibodies which block allergen-induced
IgE-dependent histamine release from basophils [22],
and grass SLIT has been shown to reduce serum eosino-
phil cationic protein levels during pollen season [23]. In
addition, grass SLIT-T has been found to induce marked
and sustained increases of Phleum pratense-specific IgG4
as well as IgE-blocking factor, immunomodulatory effects
leading to possible immune deviation and tolerances of the pooled adult-pediatric 2009 trials and the adult-
009 trials Adult-pediatric 2012 trial
PBO (n =56) Grass SLIT-T (n =142) PBO (n =140)
25 (44.6) 93 (65.5) 69 (49.3)
8 (14.3) 70 (49.3) 32 (22.9)
0 7 (4.9) 4 (2.9)
2 (3.6) 30 (21.1) 6 (4.3)
2 (3.6) 20 (14.1) 5 (3.6)
0 24 (16.9) 6 (4.3)
1 (1.8) 4 (2.8) 6 (4.3)
1 (1.8) 47 (33.1) 10 (7.1)
2 (3.6) 6 (4.2) 9 (6.4)
2 (3.6) 6 (4.2) 2 (1.4)
adverse event.
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[10]. The T-cell response is thought to account for
disease modification. In 40 trial participants treated
with grass SLIT-T, a short-term increase in cytokine-
producing (TH2) cell frequency and sIgE levels oc-
curred at Month 1, followed by downregulation of TH2
frequency from Month 4 onward through 2 years of
therapy [24]. Allergen immunotherapy targets the im-
mune system and the underlying cause of AR/C. An
induction period (ie, preseasonal treatment) is required
to induce clinically relevant immunologic changes [25],
and in general, immunologic changes can be observed
in vitro as early as 28 days after treatment initiation.
However, clinical study experience indicates that an
induction period longer than 28 days is required [26,27].
A treatment effect may be observed with preseasonal
treatment of 8 weeks, which further improves with at
least 12 weeks of preseasonal treatment. Reduction of
symptom and medication scores increased with longer
preseasonal treatment, which is evident in a mixed
regression model with the P-value approaching zero
that was used to analyze data from three trials [26].
The preseasonal treatment period was approximately
eight weeks in one trial [21], approximately 12 weeks
in a second trial [18], and 16 to 35 weeks in a third trial
[28]. Sustained immunological and clinical post-treatment
effect for at least 2 years may require up to 3 years of
continuous (year-round) treatment [10].
Grass SLIT-T provides an effective new modality for
treating grass pollen–allergic individuals with Timothy
(and other cross-reactive Festucoideae) grass-pollen–
induced AR/C. Once-daily treatment with grass SLIT-T
does not require up-titration of the administered dose,
which simplifies the treatment regimen. In addition,
only the first dose of grass SLIT-T is administered in
the physician’s office, whereas subsequent doses are
self-administered at home. Overall safety profiles of
grass SLIT-T in the studies were similar, and no new
safety concerns emerged from the studies. Local appli-
cation site reactions (eg, oral pruritus) were the most
common TRAEs; these events were generally mild to
moderate in severity and tended to occur early in treat-
ment. The two participants in the 2012 study who dis-
continued treatment due to a systemic allergic reaction
recovered on their own completely with no need for
treatment or additional medication.
Grass SLIT-T significantly improved AR/C caused by
grass pollen in Canadian adults and children aged 5 to
65 years. Improvement was shown early in the grass
pollen season and was maintained throughout the sea-
son, with a similar or greater treatment effect during the
peak pollen exposure. The treatment was well tolerated
for up to 34 weeks of treatment, and no new safety sig-
nals emerged from these trials. In conclusion, the dataindicate that grass SLIT-T provides an effective and
well-tolerated new immunotherapy modality for treating
participants with grass-pollen–induced AR/C.
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